FN2 Earnings Intelligence
Abbott Laboratories ratios (quarterly)
Abbott Laboratories (ABT) Ratios (quarterly) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 est. | 12/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $6,532 | $6,951 | $7,511 | $6,803 | $5,104 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $10,358 | $11,142 | $11,369 | $11,164 | $12,593 | $12,990.8 | $13,542.5 |
| % Growth | - | - | - | - | - | 14.3% | - |
| Gross Profit | $5,890 | $6,288 | $6,294 | $6,274 | $7,268 | - | - |
| % Margin | 56.9% | 56.4% | 55.4% | 56.2% | 57.7% | - | - |
| EBITDA | $2,029 | $2,409 | $2,428 | $1,726 | $2,095 | - | - |
| % Margin | 19.6% | 21.6% | 21.4% | 15.5% | 16.6% | - | - |
| Net Income | $1,325 | $1,779 | $1,644 | $1,077 | $928 | - | - |
| % Margin | 12.8% | 16.0% | 14.5% | 9.6% | 7.4% | - | - |
| Diluted EPS | $0.76 | $1.01 | $0.94 | $0.61 | $0.53 | $1.42 | $1.64 |
| % Growth | - | - | - | - | - | 51.0% | - |
| Operating Cash Flow | $1,417 | - | - | $1,315 | - | - | - |
| CapEx | $484 | - | - | $399 | - | - | - |
| Free Cash Flow | $933 | - | - | $916 | - | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 est. | 12/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $10,358 | $11,142 | $11,369 | $11,164 | $12,593 | $12,990.8 | $13,542.5 |
| Gross Profit | $5,890 | $6,288 | $6,294 | $6,274 | $7,268 | - | - |
| EBITDA | $2,029 | $2,409 | $2,428 | $1,726 | $2,095 | - | - |
| Net Income | $1,325 | $1,779 | $1,644 | $1,077 | $928 | - | - |
| Diluted EPS | $0.76 | $1.01 | $0.94 | $0.61 | $0.53 | $1.42 | $1.64 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $6,532 | $6,951 | $7,511 | $6,803 | $5,104 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $12,736 | $12,930 | $11,596 | $29,638 | $29,603 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | $1,417 | - | - | $1,315 | - |
| Capital Expenditure | $484 | - | - | $399 | - |
| Free Cash Flow | $933 | - | - | $916 | - |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Gross Margin | 56.9% | 56.4% | 55.4% | 56.2% | 57.7% |
| EBITDA Margin | 19.6% | 21.6% | 21.4% | 15.5% | 16.6% |
| Net Margin | 12.8% | 16.0% | 14.5% | 9.6% | 7.4% |
| FCF Margin | 9.0% | - | - | 8.2% | - |
| Diluted EPS Growth | - | - | - | - | - |